Dr Salman Tamaddon-Jahromi
Dr Salman Tamaddon-Jahromi was Neurodegeneration Experimental Lead in the Open Targets Validation Lab at the Wellcome Sanger Institute, where he generated robust experimental evidence to support therapeutic target validation in Alzheimer’s and Parkinson’s disease. He specialises in high-throughput CRISPR–Cas9 functional genomics and human iPSC-derived neuronal systems, developing scalable, quality-controlled workflows that integrate automation, high-content imaging and computational analysis.
He is currently a postdoctoral research associate in the Department of Pharmacology, University of Cambridge, where he develops human iPSC-derived hypothalamic neuron models to study obesogenic mechanisms associated with insulin and leptin resistance.
He holds a PhD in molecular and cell biology and an MSc in tissue engineering from Swansea University.
Contact info
ArticleTurning CRISPR hits into confident drug discovery decisions
Functional genomics is central to modern drug discovery, yet high attrition rates persist. In this article, Dr Salman Tamaddon-Jahromi, a postdoctoral research associate at the University of Cambridge, discusses how end-to-end CRISPR screening strategies, iPSC-derived neuronal models and layered quality control can convert functional genomics signals into actionable therapeutic hypotheses.